SG/PUT/VERTEX PHARMACEUTICALS/300/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 20:36:59 31/05/2024 BST | ||
| 0.1 EUR | -16.67% |
|
| 1 month | -75.00% | ||
| 3 months | -69.70% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 0.1 | -16.67% |
| 30/05/24 | 0.12 | +9.09% |
| 29/05/24 | 0.11 | -8.33% |
| 28/05/24 | 0.12 | +46.34% |
| 27/05/24 | 0.082 | -36.92% |
Delayed Quote Deutsche Boerse AG
Last update May 31, 2024 at 08:36 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SV6Q1H |
| ISIN | DE000SV6Q1H1 |
| Date issued | 24/05/2023 |
| Strike | 300 $ |
| Maturity | 20/09/2024 (110 Days) |
| Parity | 10 : 1 |
| Emission price | 3.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.51 € |
|---|---|
| Lowest since issue | 0.036 € |
| Spread | 0.012 € |
| Spread % | 10.91% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Warrants
- Warrant
